Stephen Gould

As a transition point between the bench and the clinic, the translational oncology group is focused on providing data that determines the relative efficacy of potential agents and correlates efficacy with target inhibition and drug exposures to help inform clinical strategy. We work closely with our discovery colleagues in Cancer Immunology and Molecular Oncology to identify ways to combine our drugs to combat drug resistance.

Embedded within the translational group we also have laboratories dedicated to developing tumor specific antibodies conjugated to a variety of drug payloads targeting key vulnerabilities within the cancer cells. We are also focused on developing a class of bi-specific antibodies that can redirect T-cells, and other immune cells, to selectively target tumors.

• University of California, San Francisco, Department of Orthopedic Surgery, Postdoctoral Fellow – 1998
• University of Virginia, Department of Biology, Postdoctoral Fellow – 1996
• University of Connecticut Health Center, Department of Developmental Biology, Ph.D. – 1993
• University of Massachusetts, North Dartmouth, B.S. – 1986

• Co-recipient of 2012 Drug Discovery of the Year Award by the British Pharmacological Society (BPS) – 2012
• New Investigator Award, Orthopedic Research Association – 1998
• American Cancer Society Postdoctoral Fellowship – 1995-1998
• Neural Behavior and Development Training Grant Postdoctoral Fellowship – 1994-1995
• Lepow Award for Outstanding Achievement, University of Connecticut Health Center – 1992
• Pre-doctoral Fellowship, University of Connecticut Health Center – 1989-1991